Protecting Our Essential Medicines Act

Bill 118 s 5419, also known as the "Country of Origin of Critical Drugs Act," is a proposed piece of legislation that aims to address concerns about the sourcing of critical drugs in the United States. The bill would require the Secretary of Health and Human Services to create and maintain a list of the country of origin for certain critical drugs that are marketed in the US.

The purpose of this list is to provide transparency and information to consumers, healthcare providers, and policymakers about where these critical drugs are manufactured. This information is seen as important for ensuring the safety and security of the US drug supply chain, as well as for understanding potential vulnerabilities in the event of supply chain disruptions or other emergencies.

In addition to creating the list of country of origin for critical drugs, the bill also includes provisions for the Secretary of Health and Human Services to work with other federal agencies, industry stakeholders, and international partners to address any concerns or issues related to drug sourcing and supply chain security. Overall, the Country of Origin of Critical Drugs Act is aimed at improving transparency and oversight in the pharmaceutical industry, with the goal of ensuring the safety and reliability of critical drugs in the United States.